AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03533790
Drug: DEP-Ru
RxNorm normalized name: estradiol cypionate / testosterone cypionate Injectable Solution [Dep Androgyn]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Drug: ruxolitinib~* Drug: doxorubicin~* Drug: etoposide~* Drug: methylprednisolone
Trial: NCT06673927
Drug: YZJ-1139
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose, 2mg, 5mg, 10mg, 20mg, 40mg, 60mg, 80mg
Trial: NCT06673927
Drug: YZJ-1139
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple Dosing ，Each oral dose of 10 mg，20 mg，40 mg or 60 mg
Trial: NCT06673927
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration
Trial: NCT00928980
Drug: Optimal Medical Care
RxNorm normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic dose of antidepressant medication
Trial: NCT01133639
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care
Trial: NCT01133639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus standard of care
Trial: NCT00918723
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01003249
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg.
Trial: NCT03421613
Drug: 3VM1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self treatment 3 times daily for 10 days
Trial: NCT01378390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration will be preceded by localization and closure of the internal opening following Major Ambulatory Surgery standards. Subjects will be receiving one treatment cycle with placebo consisting of intralesional instillation of 5 ml saline solution. Patients without healing (complete fistula closure) following week 12 assessment will continue to receive standard of care until the primary assessment of fistula closure at week 24. Patients with incomplete fistula closure at week 24 will be offered the possibility of participating in a separate open-label, single arm study using the ASCs derived from the liposuction procedure.
Trial: NCT01516450
Drug: GSK1550188 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV dose of belimumab 200 mg
Trial: NCT03102736
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo saline
Trial: NCT00862381
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: hemisuccinate d'hydrocortisone, 200mg per 24 hours, 48 hours of treatment
Trial: NCT00862381
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9%
Trial: NCT01025778
Drug: Cyclophosphamide for remission induction
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03722680
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04097288
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT00884507
Drug: RO5313534
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg po daily for 24 weeks
Trial: NCT00884507
Drug: RO5313534
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg po daily for 24 weeks
Trial: NCT00884507
Drug: RO5313534
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg po daily for 24 weeks
Trial: NCT03161418
Drug: KSP-910638G, 0.4 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (0.4 mg dose)
Trial: NCT00809757
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 actuations)
Trial: NCT01924325
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04679129
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT03156023
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection once every 2 weeks.
Trial: NCT01496352
Drug: DFA-02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified release product containing gentamicin and vancomycin for application at the conclusion of surgery after closure of the fascia and prior to skin closure
Trial: NCT01496352
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFA-02 placebo
Trial: NCT02433353
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Look-alike venlafaxine XR tablets containing no active drug
Trial: NCT03161418
Drug: KSP-910638G, 1.2 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (1.2 mg dose)
Trial: NCT01287585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weekly, intramuscular, until disease progression or toxicity.
Trial: NCT01438411
Drug: Cholic Acid
RxNorm normalized name: Cholic Acid
DrugBank: Cholic Acid (DB02659)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10-15 mg/kg body weight/day supplied in 50 or 250 mg Cholic Acid Capsules
Trial: NCT04655586
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: standard of care heparin per institution (therapeutic or prophylactic regimen)
Trial: NCT01464697
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator, taken as 3 round capsules at bedtime daily for 12 weeks
Trial: NCT01050062
Drug: Hydrochlorothiazide 12.5mg
RxNorm normalized name: HYDROCHLOROTHIAZIDE 12.5MG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablet
Trial: NCT01819961
Drug: MCT/LCT
RxNorm normalized name: lipid emulsion MCT/LCT (1:1)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03656640
Drug: Gammanorm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients already receiving Gammanorm will be observed over the course of 2 years every 3 months. Gammanorm will be given standard of care.
Trial: NCT00865501
Drug: spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg per oral once daily
Trial: NCT02410369
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following randomization, subjects with HLA-A\*2402 in the investigational arm will receive the subcutaneous administration of Placebo.
Trial: NCT02677701
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500mg tablet over-encapsulated to match placebo
Trial: NCT02677701
Drug: placebo (for azithromycin)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02677701
Drug: inhaled tobramycin
RxNorm normalized name: tobramycin Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clinically prescribed inhaled tobramycin used by subjects participating in the study
Trial: NCT01849848
Drug: SyB L-0501
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The administration of SyB L-0501 at 90 mg/m\^2/day by 60-minute intravenous infusion for 2 consecutive days followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 times. Dose reduction or discontinuation is permitted from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle.
Trial: NCT02796144
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebos will be administered for each drug.
Trial: NCT03667677
Drug: Tandospirone + Amlodipine
RxNorm normalized name: Tandospirone
DrugBank: Tandospirone (DB12833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).
Trial: NCT03971617
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablet
Trial: NCT02453789
Drug: Alginate oligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of dry powder for inhalation (DPI)
Trial: NCT02453789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02595203
Drug: [14C-pos 1]-Debio 1450 BES Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A solution containing Debio 1450 bis ethanolamine salt (BES) radiolabelled with carbon-14 (14C) at position 1
Trial: NCT02595203
Drug: [14C-pos 25]-Debio 1450 BES Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A solution containing Debio 1450 BES radiolabelled with carbon-14 (14C) at position 25
Trial: NCT03667677
Drug: Tandospirone placebo + Amlodipine placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The fourth group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).
Trial: NCT00184054
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic Acid 1000 mg every other day for 25 days
Trial: NCT01169870
Drug: Genexol-PM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment is given in the outpatient setting. Patients receive treatment every 3 weeks up to 6 cycles.
Trial: NCT01985685
Drug: Thiamine
RxNorm normalized name: Thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg IV thiamine
Trial: NCT00744367
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sc once weekly
Trial: NCT02231203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 infusions, 2 ml/kg, one the night before operation and one the day after operation
Trial: NCT01188798
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
Trial: NCT00939172
Drug: TTP607
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.3 mg/m\^2 given by central venous catheter over 1-4 hours, each day for 5 days in a row, for a 15 day cycle.
Trial: NCT00611130
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets twice daily for 9 weeks
Trial: NCT03046238
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine
Trial: NCT02017249
Drug: arginine in powder form
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02017249
Drug: Silica and cellulose placebo powder
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02553915
Drug: EPA 1 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid extracted from fish oil, 1 g/day
Trial: NCT02553915
Drug: EPA 2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid extracted from fish oil, 2 g/day
Trial: NCT02553915
Drug: EPA 4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid extracted from fish oil, 4 g/day
Trial: NCT03085732
Drug: Irrigation with Saline Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During hysterectomy after vaginal cuff closure 500-1000 mL saline irrigation will be done.
Trial: NCT00153166
Drug: placebo/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo orally three times daily
Trial: NCT02660359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
Trial: NCT02660359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
Trial: NCT01748695
Drug: V158866
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01748695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01335711
Drug: ChronVac-C + SOC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMP: I.m. administration of 500 μg plasmid DNA vaccine CHRONVAC-C (solution for injection) administered i.m. in combination with electroporation using MedPulser® DDS on 2 occasions with 4 weeks in between followed by standard of care (SOC) initiation after 14 - 42 days.~SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)
Trial: NCT01335711
Drug: SOC
RxNorm normalized name: Isocet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)
Trial: NCT00761501
Drug: Naproxen (Proxen S)
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00761501
Drug: Naproxen (Naprosyn E)
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01070355
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules taken twice daily for 2-6 weeks before liver resection.
Trial: NCT03618225
Drug: placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pill orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure
Trial: NCT00997412
Drug: Mycophenolic acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 mg/tablet, 4 tablets twice daily
Trial: NCT03604328
Drug: PA5108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single ocular implant, administered on day 1
Trial: NCT02747628
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
Trial: NCT02747628
Drug: transdermal therapeutic system- melatonin.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
Trial: NCT00399802
Drug: ZA matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV infusion of ZA matching placebo given at the start of treatment
Trial: NCT00492921
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00652093
Drug: opana then darvocet then placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
Trial: NCT00652093
Drug: Placebo then darvocet then opana
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
Trial: NCT00652093
Drug: Darvocet then opana then placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
Trial: NCT00652093
Drug: Darvocet then placebo then opana
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
Trial: NCT03649971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo SC will be administered every 4 weeks.
Trial: NCT03167164
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Trial: NCT03167164
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Trial: NCT03167164
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Trial: NCT02536508
Drug: BGF MDI 320/14.4/9.6 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide, Glycopyrronium, and Formoterol Fumarate
Trial: NCT02536508
Drug: GFF MDI 14.4/9.6 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium and Formoterol Fumarate
Trial: NCT02536508
Drug: BFF MDI 320/9.6 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide and Formoterol Fumarate
Trial: NCT04570449
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg capsule
Trial: NCT04570449
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluoxetine placebo capsule
Trial: NCT01346137
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 mg versus 30 mg per day P.O. for 15 days during 3 menstrual cycles
Trial: NCT02064218
Drug: Anti-hypertensive drugs
RxNorm normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02924675
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses daily with lactose
Trial: NCT01070875
Drug: Variation of heparin dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous two times a day.
Trial: NCT01070875
Drug: Variation of heparin dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
Trial: NCT00477529
Drug: ABI-008
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-docetaxel
Trial: NCT03562780
Drug: Fortolin Tab 500mg
RxNorm normalized name: Fortolin 500 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortolin Tab 500mg is a generic product manufactured by Fortune Pharmacal Co. Ltd.
Trial: NCT03562780
Drug: Panadol Caplet 500mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panadol Caplet 500mg is manufactured by GlaxoSmithKline (Dungarvan) Ltd.
Trial: NCT03956303
Drug: Chirocaine %0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 8 mg Chirocaine (% 0.5) +20 mcg fentanyl
Trial: NCT02973958
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See active comparator description
Trial: NCT02973958
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: See active comparator description
Trial: NCT03488810
Drug: Non-steroidal anti-androgen
RxNorm normalized name: Anti-androgens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-androgen (e. g. flutamide, bicalutamide) PO daily for 4 weeks, started 2 weeks before the first LHRH agonist injection
Trial: NCT00472927
Drug: Premarin/MPA 0.45 mg/1.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no